Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Xalkori Joins The Six-Figure Oncology Drug Club

Executive Summary

The roll-out of Pfizer Inc.’s new personalized non-small cell lung cancer therapy Xalkori blends right in with the prevailing trends in cancer drug launches, proving that six-figure pricing now seems to be the new black in oncology.

You may also be interested in...

Oncology PROs: Limited Use Due To Small Trials, Fast Drug Development

Patient-reported outcomes in oncology clinical trials remain an infrequently used tool, despite acknowledgement by sponsors that the patient experience is important to measure – and encouragement from FDA officials to do so. The lack of PROs in oncology may be a byproduct of the fast pace of cancer drugs are developed in the U.S.: small trials and accelerated pathways.

Genentech’s Alecensa Joins The ALK Inhibitor Market

Alectinib will launch within two weeks for second-line ALK-positive non-small lung cancer at the price of $12,500 per month.

Questioning Stivarga’s Cost-Effectiveness In Colon Cancer

The high cost of colon cancer drugs is once again under fire, this time with Bayer and Onyx in the hot seat. In a Lancet editorial accompanying pivotal trial results for regorafenib, U.K. authors doubt the modestly efficacious drug will ever prove cost-effectiveness in colon cancer, but that its role in GIST looks more compelling.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts